Lupin and Lilly expand partnership in India

Exclusive licensing agreement with Eli Lilly will enable Lupin to commercialise and distribute Cialis

Lupin has launched Cialis (tadalafil), an oral PDE5 inhibitor, for the treatment of erectile dysfunction (ED) in adult males. Cialis was shown to improve erectile function compared to placebo up to 36 hours following dosing. Cialis tablet is available in 10 mg and 20 mg strengths. The product is currently marketed in over 100 countries.

Lupin has acquired the rights to market, promote and distribute Lilly’s Erectile Dysfunction (ED) product, Cialis through its speciality field force while Lilly will be responsible for manufacturing and importing the product. Lupin is already promoting and distributing Lilly’s Huminsulin range of products and rapid acting insulin analog under the brand names Lispro and Eglucent.

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin said, "We are happy with the addition of Cialis to our business portfolio. It heralds Lupin’s entry into the fast growth PDE-5 inhibitors market which will address the unmet medical need in ED space in India. The launch demonstrates Lupin’s commitment to grow its brand franchise in India and bring meaningful products to patients in the country."

"We are pleased to expand our relationship with Lupin, with whom we have successfully partnered in the past. Cialis is a new treatment option for men with ED. Today, Erectile dysfunction is a significant medical condition affecting large number of Indian men, this partnership will help expand our reach to more patients. Lilly is committed to bringing innovative products to India" said Edgard Olaizola, MD, Eli Lilly and Company (India).